Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Morphine + bupivacaine is a combination medication used for pain management, particularly in spinal anesthesia. This combination leverages the different mechanisms of action of both drugs to provide enhanced analgesia while potentially reducing the required doses of each individual component. Bupivacaine is a potent, long-acting local anesthetic that blocks voltage-gated sodium channels in nerve roots and dorsal root ganglia. Morphine is an opioid that acts through G-protein coupled mu-opioid receptors, closing voltage-gated calcium channels primarily in Rexed's laminae I-II of the spinal cord. When administered intrathecally (into the spinal fluid), this combination provides effective intraoperative pain relief and prolonged postoperative analgesia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on morphine + bupivacaine.